Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
624 INR | +20.00% | +21.55% | +23.71% |
09:12am | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
05-13 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2022 | 12K 1M 957K | Sales 2023 | 19.45K 1.62M 1.55M | Capitalization | 25B 2,087B 1,994B |
---|---|---|---|---|---|
Net income 2022 | 1.22B 102B 97.57B | Net income 2023 | 1.94B 162B 154B | EV / Sales 2022 * | - |
Net Debt 2022 | 2.58B 215B 206B | Net Debt 2023 | 1.52B 127B 121B | EV / Sales 2023 | 1,363,395 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
12.9
x | Employees | 2,042 |
Yield 2022 * |
-
| Yield 2023 |
0.73% | Free-Float | 52.08% |
1 day | +20.00% | ||
1 week | +21.55% | ||
Current month | +21.62% | ||
1 month | +35.63% | ||
3 months | +23.24% | ||
6 months | +59.20% | ||
Current year | +23.71% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 16/10/22 | |
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 16/10/22 |
Piyush Lakhani
DFI | Director of Finance/CFO | - | 16/10/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 16/10/22 |
Chairman | 49 | 06/08/21 | |
Director/Board Member | 77 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/05/24 | 624 | +20.00% | 7 052 186 |
13/05/24 | 520 | +3.50% | 476,891 |
10/05/24 | 502.4 | +2.01% | 158,266 |
09/05/24 | 492.6 | -2.42% | 93,188 |
08/05/24 | 504.8 | -1.68% | 121,834 |
Delayed Quote NSE India S.E., May 14, 2024 at 10:19 am
More quotes1st Jan change | Capi. | |
---|---|---|
+23.71% | 564M | |
+29.98% | 682B | |
+31.77% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.51% | 240B | |
+9.40% | 209B | |
-8.79% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- AARTIPHARM Stock